1088993-89-8

Upstream product

• 501-53-1 benzyl chloroformate 
• 278789-37-0 (6-methyl-piperidin-3-yl)methanol 

Downstream Products

• 1088993-91-2 benzyl (2R,5R)-5-(((5-fluoro-pyridin-2-yl)oxy)methyl)-2-methyl-piperidine-1-carboxylate 
• 1088993-98-9 ((3R,6R)-6-methylpiperidin-3-yl)-methanol 
• 1088994-45-9 3-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)carbonyl)-4-pyrimidin-2-yl-benzyl acetate 
• 1088994-32-4 methyl 3-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)carbonyl)-4-pyrimidin-2-yl-benzoate 
• 1088991-76-7 3-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)carbonyl)-4-pyrimidin-2-yl-benzoic acid 
• 1088991-77-8 (3-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methy)-2-methyl-piperidin-1-yl)carbonyl)-4-pyrimidin-2-yl-phenyl)-methanol 
• 1088991-74-5 3-[(2R,5R)-5-(5-fluoro-pyridin-2-yloxymethyl)-2-methyl-piperidine-1-carbonyl]-4-[1,2,3]triazol-2-yl-benzoic acid 
• 1088994-26-6 methyl 3-[(2R,5R)-5-(5-fluoro-pyridin-2-yloxymethyl)-2-methyl-piperidine-1-carbonyl]-4-[1,2,3]triazol-2-yl-benzoate 
• 1088991-75-6 C₂₂H₂₄FN₅O₃ 
• 1088994-30-2 2-(4-bromo-2-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methyl-piperidin-1-yl)carbonyl)phenyl)pyrimidine 
• 1088994-43-7 4-bromo-3-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methyl-piperidin-1-yl)carbonyl)benzyl acetate 
• 1088991-71-2 2-(2-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methyl-piperidin-1-yl)carbonyl)-4-methylphenyl)pyrazine 
• 1088994-24-4 2-((3R,6R)-1-(5-bromo-2-(2H-1,2,3-triazol-2-ylbenzoyl)-6-methyl-piperidin-3-yl)methoxy)-5-fluoro-pyridine 
• 1088991-70-1 5-fluoro-2-(((3R,6R)-6-methyl-1-(5-methyl-2-(2H-1,2,3-triazol-2-yl)-benzoyl)-piperidin-3-yl)-methoxy)-pyridine 

Relevant academic research and scientific papers

OXAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

OXAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS

The present invention is. directed to pyridyl piperidine compounds of formula (I) which are antagonists of orexin receptors, and which are useful' in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.